June 2017

New Product - Onivyde

Onivyde (nanoliposomal irinotecan as sucrosofate) is a topoisomerase inhibitor formulated into a liposomal dispersion for intravenous use. Onivyde has been shown to extend circulation of irinotecan and prolong the duration of active therapy at the site of tumour cells to inhibit tumour growth. Onivyde is not equivalent to nonliposomal irinotecan formulations and should not be interchanged. Onivyde is indicated for treatment of metastatic adenocarcinoma of the pancreas, in combination with 5-fluorouracil and folinic acid (leucovorin) in adults who have been previously treated with gemcitabine based therapy. Onivyde is available as one 10 mL vial containing irinotecan sucrosofate equivalent to 43 mg irinotecan (or 50 mg irinotecan hydrochloride trihydrate).

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au